Pulmonology Section, Hospital San Pedro de Alcántara, Cáceres, Spain; Biomedical Research Center Network for Respiratory Diseases (CibeRes), Spain.
Pulmonology Section, Complejo Hospitalario de Ourense, Spain.
Lung Cancer. 2014 May;84(2):182-9. doi: 10.1016/j.lungcan.2014.02.006. Epub 2014 Feb 23.
The current edition of the tumor, node and metastasis (TNM) classification of lung cancer (LC) divides the presence of metastasis (M1) into two categories: M1a and M1b, depending on its anatomical location. To assess this new classification, the survival and the M descriptors of LC patients with metastatic disease registered by the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery II (GCCB-S-II), were analyzed.
Non-small cell lung cancer (NSCLC) patients, with M1a or M1b disease, included in the GCCB-S-II, from April 2009 to December 2010, staged in accordance with the prospective staging project protocol of the International Association for the Study of Lung Cancer (IASLC), and with complete TNM staging and follow-up data, were studied. The overall survival associated with each M1 category and each M descriptor, besides other prognostic factors (sex, age, performance status [PS] and others) were analyzed by univariate and multivariate models.
640 NSCLC patients (195 M1a and 445 M1b) were included. M1b tumors had significantly worse survival than M1a tumors (p < 0.001). The prognostic value of M1 category was independent from other prognostic variables such as PS, weight loss, and others. The number of metastatic sites (isolated versus multiple) and the number of lesions (single versus multiple) in patients with isolated metastasis showed prognostic value, especially in those with brain metastasis.
The current division of the M1 category into two subsets (M1a and M1b) is warranted by their prognostic significance. The number of metastatic sites and the number of lesions in patients with isolated metastasis should be taken into account, because they also have prognostic relevance.
当前版本的肺癌(LC)肿瘤、淋巴结和转移(TNM)分类将转移(M1)的存在分为两类:M1a 和 M1b,取决于其解剖位置。为了评估这种新分类,分析了西班牙肺病学和胸外科学会 II 期支气管肺癌合作组(GCCB-S-II)登记的转移性 LC 患者的生存和 M 描述符。
纳入 2009 年 4 月至 2010 年 12 月符合国际肺癌研究协会(IASLC)前瞻性分期项目方案分期的、具有 M1a 或 M1b 疾病的非小细胞肺癌(NSCLC)患者,并具有完整的 TNM 分期和随访数据。通过单变量和多变量模型分析每个 M1 类别和每个 M 描述符与其他预后因素(性别、年龄、体能状态 [PS] 等)相关的总生存率。
共纳入 640 例 NSCLC 患者(195 例 M1a 和 445 例 M1b)。M1b 肿瘤的生存明显比 M1a 肿瘤差(p<0.001)。M1 类别的预后价值独立于其他预后变量,如 PS、体重减轻等。孤立转移患者的转移部位数量(孤立与多个)和病变数量(单发与多发)具有预后价值,尤其是脑转移患者。
目前将 M1 类别分为两个亚组(M1a 和 M1b)是基于其预后意义。孤立转移患者的转移部位数量和病变数量应考虑在内,因为它们也具有预后相关性。